The safety and efficacy of conventional intravenous cancer chemotherapy is severely limited by systemic drug toxicity.In spite of significant advances in cancer diagnosis and insights into cancer etiology, CDC statististics for the past 20 years indicate little progress in reducing cancer mortality.Indeed, lung cancer mortality for NSCLC has increased more than 75% during that time.New clinically practical treatment concepts are needed.Reported here is progress, from laboratory studies to the clinic, for intratumoral chemotherapy, a new lung cancer treatment paradigm.